Finding genetic factors that affect triple-negative breast cancer
Determining susceptibility loci in triple negative breast cancer using a novel pre-clinical model
['FUNDING_R01'] · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · NIH-11261517
Researchers are using a new genetically diverse mouse model to find which genes make triple-negative breast cancer start, grow faster, or resist treatment so future therapies can better help people with TNBC.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TENNESSEE HEALTH SCI CTR (nih funded) |
| Locations | 1 site (MEMPHIS, UNITED STATES) |
| Trial ID | NIH-11261517 on ClinicalTrials.gov |
What this research studies
This project uses a well-known TNBC mouse model crossed into a large, genetically diverse family of mice so each animal has a defined and reproducible genome. By comparing tumor behavior across these different genetic backgrounds, scientists aim to pinpoint genetic spots that modify how aggressive tumors are and how they respond to therapies. The team applies systems genetics and genomic analysis to link genetic variation with tumor traits. Results are meant to highlight human-relevant genetic factors that could guide new treatment targets or predict who may respond to specific therapies.
Who could benefit from this research
Good fit: People diagnosed with triple-negative breast cancer, especially those with aggressive or treatment-resistant tumors, are the group most likely to benefit from findings of this research.
Not a fit: Patients with non‑triple‑negative breast cancer subtypes or those needing immediate treatment changes are less likely to see direct short-term benefit from this preclinical work.
Why it matters
Potential benefit: If successful, this work could reveal genetic targets and markers that help develop better, more personalized therapies for people with triple-negative breast cancer.
How similar studies have performed: Previous single-background mouse models often failed to predict patient responses, but preliminary results from these genetically diverse mouse hybrids show promising differences that could reveal human-relevant genetic modifiers.
Where this research is happening
MEMPHIS, UNITED STATES
- UNIVERSITY OF TENNESSEE HEALTH SCI CTR — MEMPHIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAKOWSKI-HAYES, LIZA — UNIVERSITY OF TENNESSEE HEALTH SCI CTR
- Study coordinator: MAKOWSKI-HAYES, LIZA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Breast Cancer Model, Breast Cancer Patient, Breast Cancer cell line